Group 1 - The company, Bibet (688759.SH), has announced a projected net loss for the year 2025, estimating a net profit attributable to shareholders of between -166 million yuan and -136 million yuan, with a net profit excluding non-recurring gains and losses expected to be between -188 million yuan and -158 million yuan [1] - From 2022 to 2024, Bibet reported no operating revenue, with net profits attributable to ordinary shareholders of -188.34 million yuan, -172.76 million yuan, and -55.99 million yuan respectively; net profits excluding non-recurring gains and losses were -207.49 million yuan, -187.77 million yuan, and -158.05 million yuan respectively [1] - The net cash flow from operating activities for the same period was -127.67 million yuan, -127.37 million yuan, and -89.61 million yuan respectively [1] Group 2 - Bibet was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2025, issuing 90 million shares at a price of 17.78 yuan per share [2] - The total amount raised from the initial public offering (IPO) was 1.6 billion yuan, with a net amount of 1.49 billion yuan after deducting issuance costs, which was 513.47 million yuan less than originally planned [2] - The company intended to raise 2.004 billion yuan for new drug research and development, the construction of a research and development center in Qingyuan, and to supplement working capital [2]